 |
 |
 |
||||||
 |
||||||||
 |
 |
 |
 |
|||||
 |
|
|
|
|||||
|
|
|
|
|
|
|
|
|
 |
 |
|
| Our
mission is to develop our ZFP TF gene regulation and ZFN gene modification technology as a new
class of human therapeutics. Our powerful technology can also be applied
in a variety of applications to enable therapeutic product
development. We are using Enabling Technology Agreements in these
areas to provide near term revenue. |
||
|
|
|
Partnerships are very important to us.
We are taking our first therapeutic programs
forward through Phase 2 clinical trials but aim to develop these programs further with partners who provide funding or access to complementary skill sets.
Collaborations in Enabling Technologies
Our Enabling Technology Agreements allow us to leverage our technology
and provide near to mid term revenue.
Opportunities:
- ZFP TF- and ZFN-Engineered Cell Lines for the Manufacturing
of Protein Pharmaceuticals.
- Genentech
- Amgen
- Pfizer
- ZFNs for the Development of Transgenic Animals
.
back to top
|
Contact |  |
Careers | |
Site Map | |
Legal | |
Glossary |
|
|
|
|
|
|
|
|